Other languages Consolidated Gems, Inc.

Equities

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

01/05	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target	MT
29/04	Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	MT

Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	30/04
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	14/03
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	01/03
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing	05/02
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing	31/01
Cullinan Oncology Doses First Patient in Study of Advanced Solid Tumor Treatment Candidate	15/12
Insider Sell: Cullinan Oncology	09/23/09
Cullinan Oncology Gets FDA Clearance for CLN-617 Study	27/23/27
Cullinan Oncology's Q4 Loss Narrows	09/23/09
Cullinan Oncology Says US FDA Approves Investigational New Drug Application for CLN-978	25/23/25
Cullinan Oncology Posts Wider Q3 Loss; Cash, Equivalents Decline	14/22/14
Cullinan Oncology Raises Stake in Cullinan MICA Unit to 92%	25/22/25
Cullinan Oncology Swings to Profit in Q2	10/22/10
Insider Sell: Cullinan Oncology	27/22/27
Insider Sell: Cullinan Oncology	22/22/22
Cullinan Oncology Finalizes Collaboration Deal With Taiho Pharmaceutical	23/22/23
Insider Buy: Cullinan Oncology	08/22/08
Cullinan Oncology Q1 Net Loss Narrows	16/22/16
Cullinan Oncology Details Updates on Drug to Treat Lung Cancer	29/22/29
Cullinan Oncology Full-Year Net Loss Narrows	17/22/17

No results for this search